Latest news with #AurobindoPharmaLtd
Business Standard
13-05-2025
- Business
- Business Standard
Sun Pharmaceutical Industries Ltd Spurts 2.83%, BSE Healthcare index Rises 1.26%
Sun Pharmaceutical Industries Ltd has added 2.75% over last one month compared to 4.26% gain in BSE Healthcare index and 9.71% rise in the SENSEX Sun Pharmaceutical Industries Ltd rose 2.83% today to trade at Rs 1733.95. The BSE Healthcare index is up 1.26% to quote at 42121.45. The index is up 4.26 % over last one month. Among the other constituents of the index, ERIS Lifesciences Ltd increased 2.7% and Aurobindo Pharma Ltd added 2.67% on the day. The BSE Healthcare index went up 20.02 % over last one year compared to the 13.3% surge in benchmark SENSEX. Sun Pharmaceutical Industries Ltd has added 2.75% over last one month compared to 4.26% gain in BSE Healthcare index and 9.71% rise in the SENSEX. On the BSE, 37402 shares were traded in the counter so far compared with average daily volumes of 58835 shares in the past one month. The stock hit a record high of Rs 1960.2 on 30 Sep 2024. The stock hit a 52-week low of Rs 1376.75 on 04 Jun 2024.
Business Standard
06-05-2025
- Business
- Business Standard
Aurobindo Pharma Ltd Slips 3.92%, BSE Healthcare index Shed 1.06%
Aurobindo Pharma Ltd has added 8.07% over last one month compared to 3.45% gain in BSE Healthcare index and 7.28% rise in the SENSEX Aurobindo Pharma Ltd fell 3.92% today to trade at Rs 1194. The BSE Healthcare index is down 1.06% to quote at 41928.48. The index is up 3.45 % over last one month. Among the other constituents of the index, Lupin Ltd decreased 3.13% and Cipla Ltd lost 2.64% on the day. The BSE Healthcare index went up 17.28 % over last one year compared to the 9.41% surge in benchmark SENSEX. Aurobindo Pharma Ltd has added 8.07% over last one month compared to 3.45% gain in BSE Healthcare index and 7.28% rise in the SENSEX. On the BSE, 5911 shares were traded in the counter so far compared with average daily volumes of 53449 shares in the past one month. The stock hit a record high of Rs 1592.55 on 13 Sep 2024. The stock hit a 52-week low of Rs 994.35 on 07 Apr 2025.
Mint
06-05-2025
- Business
- Mint
Shares to buy or sell: Sachin Gupta of 5paisa recommends Aurobindo Pharma, BDL shares today
Stock market today: The domestic benchmark indices, Nifty 50 and Sensex, began the day on a cautious note on Tuesday, with both indices trading flat as investors awaited important global indicators, especially the start of the US Federal Reserve's two-day policy meeting later today. Geopolitical tensions between India and Pakistan also impacted investor confidence, even as foreign portfolio investors (FPIs) continued to invest in Indian stocks. The Nifty 50 index started at 24,500.75, increasing by 39.60 points or 0.16%. The Sensex also saw a slight rise, opening at 80,907.24, up by 110.40 points or 0.14%. Sachin Gupta, Senior Research Analyst at 5paisa believes Nifty 50's near-term support levels to be at 24,014 and 23,738, while resistance levels at 24,908 and 25,185. On the stocks to buy front, Sachin Gupta recommends Aurobindo Pharma Ltd, and Bharat Dynamics Ltd. Here's what Gupta says about the stock market. Nifty 50 rose by 0.5% today, driven primarily by gains in Adani group stocks, TRENT, and NBFCs such as Shriram Finance, Bajaj Finserv, and M&M. Strong earnings from Adani stocks and M&M fueled the rally. The market breadth was positive, with 38 out of the 50 Nifty stocks closing in the green. However, Kotak Mahindra Bank was the top loser, acting as a significant drag on the index. The stock experienced a sharp decline following disappointing earnings and several broker downgrades. Nifty 50 opened on a strong note and maintained its positive momentum throughout the day. Optimistic sentiment prevailed, with all sectoral indices closing in the green, except for the banking sector. Midcap stocks saw a strong rally, with the index up by 1.8%. Despite the overall strength, Nifty 50 was unable to hold above the 24,500 level and faced selling pressure. This suggests resistance at higher levels as it attempts to break out of its current range. Near-term support levels are at 24,014 and 23,738, while resistance levels are at 24,908 and 25,185. On shares to buy on Tuesday, Sachin Gupta recommends Aurobindo Pharma Ltd, and Bharat Dynamics Ltd. Aurobindo Pharma share price is showcasing a bullish technical outlook, marked by a consolidation phase within a bullish pennant pattern. This pattern suggests a possible continuation of the upward trend observed earlier. Additionally, the stock is trading above both its 100-day and 200-day exponential moving averages (EMAs), signaling a positive medium- to long-term trend. A breakout above the upper boundary of the pennant could confirm the continuation of the bullish momentum. Furthermore, indicators such as the CCI and MFI are supporting an uptrend for the medium term. Therefore, traders are advised to consider buying above ₹ 1,245 level, with a stop loss at ₹ 1,198 and potential targets of ₹ 1,315 and ₹ 1,350. Bharat Dynamics share price is displaying a strong bullish technical outlook, marked by a series of higher peaks and higher troughs over the past five weeks, indicating a solid uptrend. BDL share price is trading above its 200-day Exponential Moving Average, further supporting the bullish trend. A significant surge in volume was observed today, suggesting increased investor interest and the potential for continued upward momentum. Based on above structure, we are anticipating a bullish move in BDL shares if it remains above the ₹ 1,570 level, with potential targets at ₹ 1,635 and ₹ 1,680. Traders should place a stop loss at ₹ 1,505 for any long positions. Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision. First Published: 6 May 2025, 10:12 AM IST
&w=3840&q=100)
Business Standard
23-04-2025
- Business
- Business Standard
Aurobindo Pharma in focus: Why has the stock gained 3% in trade today?
Aurobindo Pharma Ltd share price: Shares of Aurobindo Pharma gained 2.9 per cent in trade, registering an intraday high at ₹1,222.9 on the BSE. The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Dasatinib tablets. According to the filing, Dasatinib tablets are indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy. At 12:22 PM, Aurobindo Pharma shares were trading 2.65 per cent higher at ₹1,219.6 per share on the BSE. In comparison, the BSE Sensex was up 0.20 per cent at 79,757.46. The market capitalisation of the company stood at ₹70,834.57 crore. The 52-week high of the stock was at ₹1,592.55 per share and 52-week low of the stock was at ₹994.35 per share. Eugia Pharma will be manufacturing Dasatinib Tablets of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company (BMS). The product is expected to be launched in Q1FY26. The approved product has an estimated market size of $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT. This is the 181st ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. ALSO READ | Bharti Hexacom hits all time high after 400 MHz deal with with Adani firm About Aurobindo Pharma Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 30+ manufacturing and packaging facilities. Its robust product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.
